Phathom Pharmaceuticals Inc (PHAT)

$11.08

-0.73

(-6.18%)

Market is closed - opens 7 PM, 24 Jun 2024

Insights on Phathom Pharmaceuticals Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 76.2% return, outperforming this stock by 85.4%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 243.2% return, outperforming this stock by 308.5%

Performance

  • $10.86
    $11.93
    $11.08
    downward going graph

    1.99%

    Downside

    Day's Volatility :8.97%

    Upside

    7.12%

    downward going graph
  • $6.07
    $17.02
    $11.08
    downward going graph

    45.22%

    Downside

    52 Weeks Volatility :64.34%

    Upside

    34.9%

    downward going graph

Returns

PeriodPhathom Pharmaceuticals IncSector (Health Care)Index (Russel 2000)
3 Months
7.17%
0.7%
0.0%
6 Months
31.08%
8.4%
0.0%
1 Year
-9.15%
10.5%
0.0%
3 Years
-65.27%
17.1%
-23.0%

Highlights

Market Capitalization
691.3M
Book Value
- $2.54
Earnings Per Share (EPS)
-4.46
Wall Street Target Price
22.88
Profit Margin
0.0%
Operating Margin TTM
-3658.68%
Return On Assets TTM
-51.75%
Return On Equity TTM
-3489.0%
Revenue TTM
2.6M
Revenue Per Share TTM
0.05
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-206.5M
Diluted Eps TTM
-4.46
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-5.25
EPS Estimate Next Year
-3.8
EPS Estimate Current Quarter
-1.31
EPS Estimate Next Quarter
-1.27

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 14 Wall street analysts offering stock ratings for Phathom Pharmaceuticals Inc(by analysts ranked 0 to 5 stars)
Based on 14 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
12
12
11
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 106.5%

Current $11.08
Target $22.88

Technicals Summary

Sell

Neutral

Buy

Phathom Pharmaceuticals Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Phathom Pharmaceuticals Inc
Phathom Pharmaceuticals Inc
14.11%
31.08%
-9.15%
-65.27%
-51.99%
Moderna, Inc.
Moderna, Inc.
-17.71%
41.64%
11.55%
-39.28%
857.26%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
5.07%
24.05%
34.11%
95.48%
226.11%
Novo Nordisk A/s
Novo Nordisk A/s
5.19%
37.27%
76.22%
243.21%
449.78%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
4.73%
15.66%
34.62%
148.17%
158.93%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Phathom Pharmaceuticals Inc
Phathom Pharmaceuticals Inc
NA
NA
NA
-5.25
-34.89
-0.52
NA
-2.54
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.2
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
30.68
30.68
1.46
44.13
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
49.23
49.23
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
30.3
30.3
0.53
17.09
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Phathom Pharmaceuticals Inc
Phathom Pharmaceuticals Inc
Buy
$694.8M
-51.99%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$51.1B
857.26%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$114.5B
226.11%
30.68
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$629.2B
449.78%
49.23
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$120.6B
158.93%
30.3
39.46%

Institutional Holdings

  • Medicxi Ventures Management (Jersey) Ltd

    12.75%
  • The Carlyle Group Inc

    5.97%
  • Amvescap Plc.

    5.40%
  • BlackRock Inc

    4.69%
  • Ensign Peak Advisors Inc

    3.90%
  • Vanguard Group Inc

    3.38%

Company Information

phathom pharmaceuticals, inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. the company has the rights in the united states, europe, and canada to vonoprazan, a potassium-competitive acid blocker (p-cab) that blocks acid secretion in the stomach. it is also developing vonoprazan, which is in phase iii clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of helicobacter pylori infection. the company was incorporated in 2018 and is based in buffalo grove, illinois.

Organization
Phathom Pharmaceuticals Inc
Employees
452
CEO
Ms. Terrie J. Curran
Industry
Health Technology

FAQs